WO2008041610A1 - Mélange d'un dérivé de résorcinol avec un polymère - Google Patents
Mélange d'un dérivé de résorcinol avec un polymère Download PDFInfo
- Publication number
- WO2008041610A1 WO2008041610A1 PCT/JP2007/068841 JP2007068841W WO2008041610A1 WO 2008041610 A1 WO2008041610 A1 WO 2008041610A1 JP 2007068841 W JP2007068841 W JP 2007068841W WO 2008041610 A1 WO2008041610 A1 WO 2008041610A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- polymer
- resorcinol derivative
- substituent
- carbon atoms
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 105
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 title claims abstract description 99
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 50
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 32
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 28
- 125000003827 glycol group Chemical group 0.000 claims abstract description 25
- -1 Sulphonyl group Chemical group 0.000 claims description 75
- 125000004432 carbon atom Chemical group C* 0.000 claims description 68
- 125000001424 substituent group Chemical group 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 125000003282 alkyl amino group Chemical group 0.000 claims description 19
- 229920002643 polyglutamic acid Polymers 0.000 claims description 17
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 12
- 229910052799 carbon Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000004442 acylamino group Chemical group 0.000 claims description 8
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 8
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 7
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 6
- 125000001302 tertiary amino group Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 108010064470 polyaspartate Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003303 ruthenium Chemical class 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 150000002148 esters Chemical class 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical class OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940125904 compound 1 Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 229960001755 resorcinol Drugs 0.000 description 12
- 229920001400 block copolymer Polymers 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101710113864 Heat shock protein 90 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- LZTSCEYDCZBRCJ-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazol-3-one Chemical compound OC=1N=CNN=1 LZTSCEYDCZBRCJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 150000002307 glutamic acids Chemical class 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- BGGHCRNCRWQABU-JTQLQIEISA-N (2s)-2-amino-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-JTQLQIEISA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- PJEXUIKBGBSHBS-UHFFFAOYSA-N 1-(hydroxymethyl)pyrrolidin-2-one Chemical compound OCN1CCCC1=O PJEXUIKBGBSHBS-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RBSVPKWBWJHWNY-UHFFFAOYSA-N 4,5-dihydro-3h-1,2,4-triazole Chemical compound C1NCN=N1 RBSVPKWBWJHWNY-UHFFFAOYSA-N 0.000 description 1
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- LFSWGFDRYYJMOQ-UHFFFAOYSA-N 5-propan-2-ylbenzene-1,2,4-triol Chemical compound CC(C)C1=CC(O)=C(O)C=C1O LFSWGFDRYYJMOQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- ARYZCSRUUPFYMY-UHFFFAOYSA-N methoxysilane Chemical compound CO[SiH3] ARYZCSRUUPFYMY-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000002004 n-butylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920003987 resole Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C08G73/1092—Polysuccinimides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
Definitions
- the present invention relates to a resorcinol derivative in which a carboxyl group of a copolymer of a polyethylene glycol structural part and a polymer part having a carboxyl group in a side chain and a hydroxyl group of a resorcinol derivative are ester-bonded!
- the present invention relates to a polymer conjugate, a method for producing the same, and a use thereof.
- Resorcinol derivatives are known to exhibit antitumor activity by binding to heat shock protein 90 (HSP90) family proteins and inhibiting the functions of HSP90 family proteins (Non-patent Document 1).
- HSP90 heat shock protein 90
- Known resorcinol derivatives include compounds having a pyrazole skeleton (patent documents;! To 4), an isoxazole skeleton (patent document 5), and a triazole skeleton (patent documents 6 to 8).
- natural compounds such as Geldanamycin, Radicolic (Patent Document 9), Geldanamycin derivative 17-AAG (Non-Patent Document 2), and other low molecular weight compounds can bind to HSP90 family proteins.
- Non-patent Document 3 PU3 which is a purine derivative, and derivatives thereof are known (Non-patent Document 3).
- many of these compounds are poor in water solubility even in terms of physical properties that are not sufficient for use as pharmaceuticals in terms of antitumor effects.
- 17-AAG which is in clinical trials, is administered using large amounts of DMSO.
- many compounds derived from natural products have large molecular weights and have problems with in vivo stability.
- Patent Document 10 a molecule that exhibits water solubility by combining a drug with a block copolymer of polyethylene glycol and polyaspartic acid to form micelles.
- Patent Document 10 Polyethylene glycols and polyacidic amino acids are known.
- Patent Documents 11 to 12 There is known a polymer carrier serving as a polymer drug carrier in which a hydrophobic substance is bound to a side chain carboxylic acid of a block copolymer.
- Patent Document 12 describes that the antitumor effect is different between the case where the polyacidic amino acid is polyglutamic acid and the case of polyasparagic acid. It can be seen that proper selection of the combination of encapsulating compounds is necessary to exert the effect.
- Patent Document 13 a polymer conjugate of camptothecins in which a side chain force lpoxyl group of a block copolymer of polyethylene glycols and polyglutamic acid is bound to a phenolic hydroxyl group of camptothecins.
- Patent Documents 9 to 12 describe a polymer conjugate of a resorcinol derivative! /, Which is described! /,! /.
- Patent Document 1 International Publication No. 03/055860
- Patent Document 2 International Publication No. 04/050087
- Patent Document 3 International Publication No. 04/056782
- Patent Document 4 International Publication No. 04/096212
- Patent Document 5 International Publication No. 04/072051
- Patent Document 6 International Publication No. 05/000300
- Patent Document 7 International Publication No. 06/055760
- Patent Document 8 International Publication No. 05/018674
- Patent Document 9 International Publication No. 06/095783
- Patent Document 10 Japanese Patent No. 2694923
- Patent Document 11 Japanese Patent No. 3268913
- Patent Document 12 Japanese Patent No. 3310000
- Patent Document 13 International Publication No. 04/039869
- Non-Patent Document l Hsp90 inhibitors as novel cancer chemotherapeutic age nts. Trends Mol Med. 2002; 8 (4 Suppl.): P. S55—61.
- Non-Patent Document 2 The clinical applications of heat shock protein inhibitor s in cancer ⁇ present and future. Curr. Cancer Drug Targets. 2
- Non-Patent Document 3 Vilenchik, m. Et al. Targeting wide— range oncogenic transformation via PU24FC1, A specific inhibitor of tumor Hsp90. Chem. Biol. 11, 787-797 (2004)
- the present inventors have conducted extensive research, and as a result, a copolymer of a hydroxyl group of a resorcinol derivative, a polyethylene glycol structure part and a polymer part having a carboxyl group in a side chain.
- the present invention was completed by finding a polymer conjugate of a resorcinol derivative that is ester-bonded with a carboxyl group of the above.
- the present invention relates to the following (1) to (; 11).
- R represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms which may have a substituent.
- R represents a linking group; R represents a hydrogen atom or carbon number;! To 6 acyl group or carbon number;! To 6 Represents a alkoxycarbonyl group, R represents a hydroxyl group residue of a resorcinol derivative, R
- R Represents a group selected from the group consisting of ONH (R), and R and R may be the same or different;
- R is an optionally substituted alkyl group having 1 to 6 carbon atoms, and R is 2 carbon atoms.
- An alkylene group having ⁇ 6, and R is an acyl group having 1 to 6 carbon atoms or an alcohol having 1 to 6 carbon atoms
- Xycanoreboninore t is an integer of 100 to 300
- d is 1 to:
- L00 is an integer
- e and f are each an integer of 0 to 100
- d + e + f is 6 to Is an integer of 100
- R is a box
- a polymer conjugate of a resorcinol derivative is A polymer conjugate of a resorcinol derivative.
- Resorcinol derivatives have the general formula (2)
- ring A represents a heteroaromatic ring having 5 atoms which may have a substituent
- X represents a mercapto group, a hydroxyl group, a halogen atom, a nitro group, a cyano group or a substituent.
- a carbocyclic or heterocyclic aryl group which may have a substituent, an alkyl group, an alkenyl group or an alkynyl group which may have a substituent, or an amino group or a acylamino group which may have a substituent;
- R represents the substituent shown in (8) above
- Y represents a mercapto group, a hydroxyl group, a hydrogen atom
- Halogen atom strong rubermoyl group, alkoxycarbonyl group, cyano group, alkylthio group, allylthio group, alkylsulfier group, arylsulfuryl group, alkylsulfonyl group, arylsulfonyl group, sulfamoyl group, alkoxyl group, aryloxy group, An acyloxy group, an alkoxycarbonyloxy group, a rubamoyloxy group, or an optionally substituted amino group, an acylamino group, an alkoxycarbonylamino group, a ureido group, a sulfonylamino group, a sulfamoylamino group , Forminole group, acyl group or silyl group.
- the polymer conjugate of the resorcinol derivative according to any one of the above (1), V, and (8) selected from one substituent.
- Resorcinol derivatives are represented by the formulas (5-1) to (5-21)
- An anticancer agent comprising, as an active ingredient, a polymer conjugate of the resorcinol derivative according to (1), (11)!
- the present invention provides a polymer conjugate of a resorcinol derivative that exhibits antitumor activity by inhibiting the HSP90 family and is excellent in water solubility and pharmacokinetics.
- the polymer conjugate of the present invention has improved pharmacokinetics, stability and water solubility in vivo as compared with the resorcinol derivative alone, by an appropriate combination of the copolymer and the resorcinol derivative. Therefore, the antitumor effect is maintained for a long period of time, and it is possible to administer without using DMSO, which has been conventionally required for dissolving the resornoresinol derivative alone (encapsulated compound).
- the polymer conjugate of the present invention suppresses the total dose of the encapsulated compound due to its antitumor effect over a long period of time, it is expected to reduce toxicity. Furthermore, the polymer conjugate of the present invention releases a resorcinol derivative that exhibits antitumor activity even in the absence of an enzyme.
- the polymer conjugate of the resorcinol derivative of the present invention is an ester of a hydroxyl group of a resorcinol derivative and a carboxyl group of a copolymer of a polyethylene glycol structure part and a polymer part having a carboxyl group in a side chain. Characterized by a combined structure
- Examples of the polymer moiety having a carboxyl group in the side chain in the present invention include polyacrylic acid, polymethacrylic acid, polymalic acid, polyaspartic acid, polyglutamic acid, and the like, preferably polyaspartic acid, polyglutamic acid, and the like. It is.
- the polyethylene glycol structure portion in the present invention includes polyethylene glycol modified at both ends or at one end, and the modifying groups at both ends may be the same or different.
- the terminal modifying group include a C 1-6 alkyl group which may have a substituent. Specific examples include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an s-butyl group, a t-butyl group, a benzyl group, a dimethoxyethyl group, and a diethoxyethyl group. Preferably, it has a substituent and may be! /, Carbon number; Examples thereof include a methyl group, specifically a methyl group, an ethyl group, an n-propyl group, and an i-propyl group.
- alkoxy polyethylene glycol and more preferred is methoxy polyethylene glycol.
- the molecular weight of the polyethylene glycol structural moiety is usually about 300 to 500,000, preferably ⁇ is about 500 to about 100,000, and more preferably is about 1000 to about 50,000.
- the average number of carboxyl groups per molecule of the copolymer of the polyethylene glycol structure portion and the polymer portion having a carboxyl group in the side chain is about 1 to 300,
- -200 force S is preferable, more preferably 6-60.
- the number of carboxyl groups can be determined by neutralization titration with alkali.
- the copolymer of the polyethylene glycol structure portion and the polymer portion having a carboxyl group in the side chain in the present invention includes a graft type polymer and a block type polymer, preferably a block type polymer.
- Examples of the copolymer of the polyethylene glycol structure part and the polymer part having a carboxyl group in the side chain include, for example, alkoxy polyethylene glycol polyacrylic acid, aralkoxy polyethylene glycol-polymethacrylic acid, alkoxy polyethylene glycol polymalic acid. , Alkoxy polyethylene glycol-polyaspartic acid, alkoxy polyethylene glycol polyglutamic acid, and the like. Preferred are alkoxy polyethylene glycol-polyaspartic acid and alkoxy polyethylene glycol-polyglutamic acid.
- the molecular weight of the copolymer of the polyethylene glycol structural moiety and the polymer moiety having a carboxyl group in the side chain in the present invention is usually about 500 to 500,000, preferably about 600 to about 100,000, and more preferably. ⁇ Is between 800 and 80000. In the present specification,! /, Molecular weight is a weight average molecular weight measured by GPC method.
- the binding amount of the resorcinol derivative bound to the copolymer of the polyethylene glycol structure portion and the polymer portion having a carboxyl group in the side chain is an amount exhibiting a medicinal effect. Although not particularly limited, it is usually !! to 100%, preferably 10 to 90% of the total number of carboxyl groups of the polymer. [0023]
- the definition of each group used in the present invention is described below. However, this is not the case unless otherwise noted.
- the halogen atom represents a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- the alkyl group means a chain, branched or cyclic alkyl group having 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms, unless otherwise specified.
- Examples of the chain alkyl group include a methyl group, an ethyl group, a propyl group, an n-butyl group, an n-pentyl group, and an n-hexyl group.
- Examples of the branched alkyl group include isopropyl group, tert butyl group, 2,2-dimethylpropyl group and the like.
- cyclic alkyl group examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an adamantyl group, and the like.
- the alkenyl group has a carbon-carbon double bond at one or more strengths in any force, unless otherwise indicated, a chain having 2 to 20 carbon atoms, preferably a chain having 2 to 8 carbon atoms, branched, Or a cyclic alkenyl group.
- chain alkenyl group include an alkenyl group, a 1-propenyl group, a 1-alkenyl group such as a 1-butur group, a 2-alkenyl group, and a 2-alkenyl group such as a 2-pentur group.
- Examples of the branched alkenyl group include an isopropenyl group, a 3-methyl-1-butur group, and a geranyl group.
- the alkynyl group is an alkynyl group having a carbon-carbon triple bond at one or more strengths, and having 2 to 20 carbon atoms, preferably 2 to 8 carbon atoms unless otherwise specified.
- Examples of the carbocyclic aryl group include a phenyl group and a naphthyl group.
- heterocyclic aryl group examples include a pyridyl group, pyrimidinyl group, quinolyl group, quinazolyl group, naphthyridinyl group, furyl group, pyrrolyl group, indolyl group, imidazolyl group, pyrazolyl group, oxazolyl group, isoxazolyl group, And a triazolyl group.
- Examples of the substituent when it is described that it may have a substituent include a hydrogen atom, Mercapto group, hydroxyl group, halogen atom, nitro group, cyano group, alkyl group, alkenyl group, alkynyl group, carbocyclic or heterocyclic aryl group, alkylthio group, arylthio group, alkylsulfiel group, arylsulfuryl group, alkylsulfonyl group Group, arylsulfonyl group, sulfamoyl group, alkoxyl group, aryloxy group, acyloxy group, alkoxycarbonyloxy group, strong rubamoyloxy group, amino group, acylamino group, alkoxycarbonylamino group, ureido group, sulfonyl group Examples thereof include a mino group, a sulfamoylamino group, a formyl group, an acyl
- substitution position on the aromatic ring may be ortho, meta or nora.
- the alkylthio group represents an alkylthio group having 1 to 8 carbon atoms, and examples thereof include a methylthio group, an isopropylthio group, and a benzylthio group.
- the arylthio group include a phenylthio group, a naphthylthio group, a pyridylthio group, and the like.
- the alkylsulfinyl group is an alkylsulfinyl group having 1 to 8 carbon atoms, and examples thereof include a methylsulfinyl group, an isopropylsulfinyl group, and a benzylsulfinyl group.
- the arylsulfinyl group include a phenylsulfinyl group, a naphthylsulfinyl group, and a pyridylsulfinyl group.
- the alkylsulfonyl group represents an alkylsulfonyl group having from 8 to 8 carbon atoms, and examples thereof include a methylsulfonyl group, an isopropylsulfonyl group, and a benzylsulfonyl group.
- Examples of the aryl sulfonyl group include a phenyl sulfonyl group, a naphthyl sulfonyl group, a pyridyl sulfonyl group, and the like.
- Examples of the sulfamoyl group include a dimethylsulfamoyl group and a phenylsulfamoyl group.
- the alkoxyl group represents an alkoxyl group having 1 to 8 carbon atoms, and examples thereof include a methoxyl group, an isopropoxyl group, and a benzyloxy group.
- the aryloxy group include a phenoxyl group, a naphthyloxy group, a pyridyloxy group, and the like.
- the acyloxy group has 1 to 8 carbon atoms unless otherwise specified. For example, an acetoxyl group, a benzoyloxy group, and the like.
- the alkoxycarbonyloxy group is an alkoxycarbonyloxy group having 1 to 8 carbon atoms unless otherwise specified, and examples thereof include a methoxycarbonyloxy group and a trimethoxymethoxycarbonyl group.
- Examples of the canolamomoyloxy group include a dimethylcarbamoyloxy group and a phenylcarbamoyloxy group.
- Examples of the amino group include an unsubstituted amino group, a dimethylamino group, a morpholino group, a piperidinyl group, a 4-methylbiperazine 1-yl group, a phenylamino group, and the like.
- Examples of the acyl amino group include an acetylamino group, a benzoylamino group, and the like.
- Examples of the alkoxycarbonylamino group include a methoxycarbonylamino group, an ethoxycarbonylamino group, a benzyloxycarbonylamino group, and the like.
- Examples of the ureido group include a trimethylureido group, a 1-methyl-3-phenyl ureido group, and the like.
- Examples of the sulfonylamino group include a methanesulfonylamino group and a benzenesulfonylamino group.
- Examples of the sulfamoylamino group include a dimethylsulfamoylamino group.
- Examples of the acyl group include an acetyl group, a bivaloyl group, a benzoyl group, a pyridine group and a nonyl group.
- Examples of the alkoxycarbonyl group include a methoxycarbonyl group and a benzyloxycarbonyl group.
- Examples of the strong rubamoyl group include a dimethylcarbamoyl group, a phenylcarbamoyl group, and the like.
- silyl group examples include a trimethylsilyl group, a triisopropylpropyl silyl group, a tert-butylene phenyl silyl group, and the like.
- a halogen atom, an alkyl group which may have a substituent, a rubamoyl group, a sulfamoyl group, a chlorine atom, a bromine atom, an ethyl group or an isopropyl group are preferred. Particularly preferred.
- a substituent of X in the general formula (2) a hydrogen atom or a hydroxyl group is preferable.
- R in the general formula (2) an optionally substituted phenyl group, naphthyl group,
- a pyrrolyl group and an indolyl group are preferred.
- a substituent of R in the general formula (2) a hydroxyl group
- Ring A in general formula (2) is preferably an imidazolyl group, a pyrazolyl group, a triazolyl group, or an isoxazolyl group.
- the substituent of ring A includes a hydrogen atom, a mercapto group, a hydroxyl group, an alkyl group, an alkylsulfonyl group, a strong rubamoyl group, an alkoxy group, a sulfonyl group, a hydrogen atom, a mercapto group, a hydroxyl group, and a methyl group.
- Group is particularly preferred
- the resorcinol derivative is not particularly limited as long as it is a compound having a resorcinol skeleton and having antitumor activity and the like. Resorcinol derivatives also include pharmacologically acceptable salts and prodrugs thereof.
- a preferred resorcinol derivative is a compound having a structure represented by the general formula (2). More preferably, in the above general formula (2), ring A includes, for example, structures represented by general formulas (3-1) to (37), and tautomers thereof are also included.
- a tautomer is a compound in which the respective isomers can be rapidly interconverted, and have, for example, the relationships represented by the following general formulas (41) and (42).
- R represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms which may have a substituent
- R represents a hydrogen atom, an acyl group having 1 to 6 carbon atoms or an alkoxycarbonyl group having 1 to 6 carbon atoms
- R represents a hydroxyl group residue of a resorcinol derivative
- R represents a substituent.
- R may be the same or different and is a cyclic alkyl group having 3 to 6 carbon atoms
- the alkyl group having 1 to 6 carbon atoms in R in the general formula (1) may have a substituent.
- Examples thereof include a straight chain or branched chain alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethynole group, an n propyl group, an i propyl group, an n butyl group, and a t butyl group. Or a straight chain or branched chain carbon group, preferably a branched chain alkyl group having 1 to 4 carbon atoms;! To 3 alkenoquinol groups such as a methylol group, an ethyl group, an n-propyl group, and an i-propyl group. Particularly preferred is a methyl group. An unsubstituted alkyl group or an alkyl group having an alkyl group as the substituent is preferred! /.
- the linking group represented by R in the general formula (1) is not particularly limited, and examples thereof include an alkylene group having 2 to 6 carbon atoms, and an alkylene group having 2 to 4 carbon atoms is preferable. Examples thereof include an ethylene group, a trimethylene group, and a butylene group, and a trimethylene group is particularly preferable.
- the acyl group having 1 to 6 carbon atoms in R in the general formula (1) is not particularly limited.
- a formyl group, a acetyl group, a propionyl group, a bivaloyl group and the like can be mentioned, and an acetyl group having a carbon number of !!-3 is preferred.
- Non-limiting examples include methoxycarbonyl group, ethoxycarbonyl group, and t-butoxycarbonyl.
- Examples of the body include the resorcinol derivatives described above, and any resorcinol derivative having an anti-tumor activity having a hydroxyl group that forms an ester bond with a carboxylic acid moiety of a polymer and a dehydrating condensation agent.
- R in the general formula (1) is an alkoxy group having 1 to 30 carbon atoms, an aralkyl group having 7 to 30 carbon atoms.
- Si group, optionally substituted alkylamino group having 1 to 30 carbon atoms, optionally substituted di (1 to 30 carbon atoms) alkylamino group, and carboxyl group are protected.
- R in the general formula (1) may be the same or different in one molecule, and may be a single polymer or a mixture in the polymer used for the polymer conjugate of the resorcinol derivative.
- Examples of the alkoxy group having 1 to 30 carbon atoms in R in the general formula (1) include linear or branched alkoxy groups having 1 to 30 carbon atoms, and linear or branched carbon groups;
- the alkoxy group having ⁇ 10 is preferred, for example, methoxy group, ethoxy group, n-propoxy group, i-propoxy group, n-butoxy group, t-butoxy group, etc., and aralkyloxy group having 7 to 30 carbon atoms.
- Examples of the alkyl group include linear or branched aralkyloxy groups having 7 to 30 carbon atoms, and linear or branched aralkyloxy groups having 7 to 20 carbon atoms are preferred, such as 4-phenylbutoxy group. .
- the group include a linear or branched alkylamino group having 1 to 30 carbon atoms or a di (C1 to C30) alkylamino group, and a linear or branched alkylamino group having 1 to 20 carbon atoms.
- a group or a di (C1-20) alkylamino group is preferred, for example, a methylamino group, an ethylamino group, an n-propylamino group, an i-propylamino group, an n-butylamino group, a t-butylamino group, a benzylamino group, an acetylamino group, Examples include dimethylamino group, jetylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, dibenzylamino group, and methylbenzylamino group.
- An unsubstituted alkylamino group or an alkylamino group having an alkyl group as a substituent is preferred! /.
- amino acids in which the carboxyl group in R of the general formula (1) is protected include amino acids in which the carboxyl group used in normal peptide synthesis is protected, such as phenylalanine benzyl ester and the like. It is done.
- N (R) CONH (R) R and R may be the same or different and are substituted with a cyclic alkyl group having 3 to 6 carbon atoms or a tertiary amino group.
- the alkyl group having 1 to 5 carbon atoms that may be used is not particularly limited, and examples thereof include cyclohexylamino. Examples thereof include a carbonylcyclohexylamino group and an isopropylaminocarbonylisopropylamino group.
- the total number of dartamic acids in the polymer conjugate of the resorcinol derivative represented by the general formula (1) is represented by d + e + f, and is about 3 to 200, preferably 6 to 100; The number is about 6, more preferably about 6 to 40.
- the ratio of the number d of glutamic acids bound by the resorcinol derivative to the total number of glutamic acids (d + e + f) is:! -100%, preferably 10-90%.
- t in the general formula (1) is a force that is an integer of about 5 to 11500, preferably an integer of about 8 to 2300, and more preferably an integer of about 100 to 300.
- the polymer conjugate of the resorcinol derivative represented by the general formula (1) may form a micelle having a polyethylene glycol structure portion as an outer shell in water.
- the polymer conjugate of the resorcinol derivative of the present invention comprises a dehydration condensing agent in an organic solvent containing a carboxyl group of a polymer part having a polyethylene glycol structure part and a carboxyl group in a side chain, and a hydroxyl group of a resorcinol derivative in an organic solvent.
- the production method is also included in the present invention. That is, for example, a block copolymer of a polyethylene glycol structural part polyglutamic acid prepared by the method described in Patent Document 11 and a resorcinol derivative in which a functional group other than the group to be reacted is protected as necessary is used as a solvent.
- aprotic polar solvents such as N, N dimethylformamide (DMF), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP), 0 to 180 ° C, Preferably at 5-50 ° C dicyclohexyl carpositimide (DCC), disopropyl carpomidimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) force ruperimido hydrochloride (WSC), 1 ethoxycarbon It is a production method that is subjected to a reaction using a dehydration condensing agent such as lu 2-ethoxy 1,2-dihydroxyquinolinone (EEDQ).
- a dehydration condensing agent such as lu 2-ethoxy 1,2-dihydroxyquinolinone (EEDQ).
- a reaction aid such as N, N dimethylaminopyridine (DMAP) may be used in the condensation reaction. After the condensation reaction, deprotection is performed as necessary, and a polymer conjugate of a resorcinol derivative is produced by a normal operation such as separation and purification.
- DMAP N, N dimethylaminopyridine
- R is a N (R) CONH (R) group (R and R may be the same or different, and the number of carbon atoms may be 3
- a polymer conjugate of a resorcinol derivative which is a (alkyl group) can also be obtained by a reaction using the above-mentioned carposimide as a condensing agent.
- R represents an alkoxy group having 1 to 30 carbon atoms, an aralkyloxy group having 7 to 30 carbon atoms, an alkylamino group having 1 to 30 carbon atoms, di (1 to 30) Alkyl amino group or amino acid in which the carboxyl group is protected can be introduced by activating the carboxyl group of the polymer by the above-mentioned method, and then adding the corresponding alcohol, corresponding amine or carboxyl.
- a method in which an amino acid with a protected group is reacted under basic conditions, a method in which a corresponding alcohol, an amino acid in which a corresponding amine or carboxyl group is protected, and the like are activated and then reacted with a polymer are also possible.
- After purifying the polymer it is possible to reactivate the unreacted carboxyl group in the polymer by the same reaction, and the hydroxyl group of the resorcinol derivative may be condensed here, or different alcohol, amine, etc.
- the reaction may be repeated to synthesize a hybrid of various substituents of R, and then the hydroxyl group of the resorcinol derivative may be condensed.
- An amino acid in which the amino group or carboxyl group is protected may be introduced.
- the production method of the polymer conjugate of the resorcinol derivative of the present invention is not limited to the above method.
- the present invention also includes an anticancer agent comprising the polymer conjugate of the resorcinol derivative of the present invention as an active ingredient.
- the polymer conjugate can be used in commonly used dosage forms such as injections, tablets and powders.
- Pharmaceutically acceptable carriers commonly used for formulation such as binders, lubricants, disintegrants, solvents, excipients, solubilizers, dispersants, stabilizers, suspending agents, Preservatives, soothing agents, pigments, fragrances and the like can be used.
- water saline, 5% glucose or mannitol solution
- water-soluble organic solvent eg glycerol, ethanol, dimethyl sulfoxide, N-methylol pyrrolidone, polyethylene glycol, cremophor Etc. or a mixture thereof
- water-soluble organic solvent eg glycerol, ethanol, dimethyl sulfoxide, N-methylol pyrrolidone, polyethylene glycol, cremophor Etc. or a mixture thereof
- water-soluble organic solvent eg glycerol, ethanol, dimethyl sulfoxide, N-methylol pyrrolidone, polyethylene glycol, cremophor Etc. or a mixture thereof
- the dose of the polymer conjugate of the resorcinol derivative of the present invention is determined by the sex, age, Naturally, it can be changed depending on physiological conditions, pathological conditions, etc., but parenterally, usually 0.0% as an active ingredient per day for adults;! -500 mg / m 2 , preferably 0.;!-250 mg / m 2 Administer.
- Administration by injection is performed by veins, arteries, affected areas (tumor areas) and the like.
- R trimethylene group
- R Ac (acetyl group)
- R resorcinol derivative water
- Methoxypolyethylene glycol polyglutamic acid block copolymer (the number of polymerization of glutamic acid was about 23; 1.10 g) prepared by the method described in Patent Document 12 (Reference Example 1) was dissolved in dimethylformamide (47 ml). After stirring at room temperature for a while, 5- (2,4 dihydroxy 5 isopropyl phenol) 1 4- (4 methoxy monophenyl) 1 2,4 dihydro 1 synthesized by the method described in Patent Document 8 [1 , 2, 4] triazol-13-one (260 mg), dimethylaminopyridine (28 mg), and diisopropyl carpositimide (0 ⁇ 47 m 1) were added, and the mixture was further stirred at 26 ° C. for 20 hours.
- Example 3 Compound 3 (a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12000 and a polyglutamic acid moiety having a polymerization number of about 23 and 4 (butter 2-inyl)
- R trimethylene group
- R Ac (acetyl group)
- R hydroxyl group of resorcinol derivative
- Example 1 5 (2,4-Dihydroxy-1-5-propynolephenyl) 4- (4-methoxyphenyl) -1,2,4-dihydro [1,2,4] triazol Instead of 3-one, 4-- (but-2-ynyl) -6- [4- (4 methoxy monophenyl) -5 methyl monoisoxazole 3-yl]
- Compound 3 (21.6 mg) was synthesized in the same manner as in Example 1 using benzene-1,3-diol (3.4 mg). The content in Compound 3 was 10.4% (w / w).
- Test Example 1 Release of encapsulated drug in the absence of enzyme of the compound of the present invention
- the polymer conjugate of the resorcinol compound of the present invention showed a sustained release of a resorcinol derivative (encapsulated compound) exhibiting antitumor activity even in the absence of an enzyme over several tens of hours. Confirmed to do.
- Test Example 2 Mouse colon cancer Antitumor effect on Colon26 transplanted mice
- the colon colon tumor of mouse colon cancer which was subcultured subcutaneously in BALB / cA mice, was made into a block of about 2 mm square and transplanted into the dorsal skin of CDF1 mice using a trocar.
- the polymer conjugate of the resorcinol derivative of the present invention (compound 1) and the control Encapsulated resorcinol derivative (5— (2,4 dihydroxy-5 isopropyl phenyl) —4— (4 methoxy monophenyl) 1,2,4 dihydro 1 [1,2,4] triazol 1 3 on)
- Compound 1 of the present invention was dissolved in 5% glucose injection and administered once.
- the control resorcinol derivative (encapsulated compound) was dissolved in DMSO, added with TWEEN80, diluted with 5% glucose injection, and administered once a day for 5 days. After administration, the major axis (Lmm) and short meridian (Wmm) of the tumor are measured periodically, the tumor volume is calculated by (LXW 2 ) / 2, and the average relative tumor volume on each measurement day is calculated from the tumor volume on the day of administration. (Table 1).
- the polymer conjugate of the resorcinol compound of the present invention suppressed tumor growth for a long time with a single administration and was more effective than the effect of daily administration of resorcinol derivative (encapsulated compound) for 5 days.
- the tumor effect was enhanced.
- the polymer conjugate of the resorcinol compound has improved pharmacokinetics and stability in vivo compared with the resorcinol derivative, and has maintained the antitumor effect for a long period of time.
- the polymer conjugate of resorcinol compound has increased water solubility compared to the resorcinol derivative, and it was possible to administer without using DMSO, which was conventionally required to dissolve the inclusion compound. .
- the precipitate was collected by filtration and washed with ethanol / diisopropyl ether (l / 4 (v / v), 100 ml). Washed. The obtained precipitate was dissolved in DMF (20 ml), acetic anhydride (0.4 ml) was added, and the mixture was stirred at room temperature for 15 hours. Ethanol (80 ml) and diisopropyl ether (320 ml) were added to the reaction mixture, and the mixture was stirred at room temperature for 90 minutes. The precipitate was collected by filtration and washed with ethanol / diisopropyl ether (l / 4 (v / v), 100 ml). By washing, 1.56 g of polymer was obtained.
- the obtained polymer was dissolved in DMF (47 ml), 5% palladium on carbon (780 mg) was added, and hydrogenolysis was performed at 35 ° C for 3 hours.
- Methanol (90 ml) and celite (8 g) were added to the reaction solution, and the mixture was stirred for 2 hours, and then 5% palladium carbon was filtered off. After methanol was distilled off under reduced pressure, ethanol (90 ml) and diisopropyl ether (360 ml) were added, and the mixture was stirred at room temperature for 90 minutes.
- the precipitate was collected by filtration, washed with ethanol / diisopropyl ether (1/4 (v / v), 100 ml), and dissolved in 10% saline (100 ml). After adjusting the pH of the solution to 10.0 with 1N aqueous sodium hydroxide solution, the solution is purified using partition adsorption resin column chromatography, the eluted solution is concentrated under reduced pressure, and freeze-dried to obtain the target compound (1 18 g) was obtained. Based on titration with a 0.02N aqueous sodium hydroxide solution, the number of polymerizations of glutamic acid in one molecule of this compound was about 28. The number of polymerizations of glutamic acid in one molecule of this compound can be controlled by adjusting the equivalent amount of monobenzyl L glutamate N strength rubonic acid anhydride.
- FIG. 1 Compound 1 of the present invention (the encapsulated resorcinol derivative is 5- (2,4 dihydroxy 1-5 isopropylinophenol) 1 4 1 (4-methoxyphenolinole) 1, 2, 4 dihydro [1, 2, 4] Triazol-3-one (polymer conjugate of formula (5-3)), Compound 2 (encapsulated resorcinol derivative is 4 1 ⁇ 5-Hydroxy 4 [4 (Morpholine 4 yl) —Phenyl] — 4H— [1,2,4] Triazol-3-yl ⁇ — 6-Isopropyl monobenzene 1,3-diol (polymer conjugate of formula (5-8))), compound 3 (encapsulated resorcinol) The derivative is 4 (but-2-ynyl) -6- [4- (4-methoxymonophenyl) 5-methyl-isoxazol 3-yl] benzene 1,3-diol (formula (5-19
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002664852A CA2664852A1 (en) | 2006-10-03 | 2007-09-27 | High-molecular weight conjugate of resorcinol derivatives |
ES07828587.1T ES2584840T3 (es) | 2006-10-03 | 2007-09-27 | Compuesto de un derivado de resorcinol con un polímero |
JP2008537500A JP5548364B2 (ja) | 2006-10-03 | 2007-09-27 | レゾルシノール誘導体の高分子結合体 |
EP07828587.1A EP2070971B1 (en) | 2006-10-03 | 2007-09-27 | Compound of resorcinol derivative with polymer |
US12/311,086 US20090239782A1 (en) | 2006-10-03 | 2007-09-27 | High-molecular weight conjugate of resorcinol derivatives |
US14/497,703 US20150011715A1 (en) | 2006-10-03 | 2014-09-26 | High-Molecular Weight Conjugate Of Resorcinol Derivatives |
US15/159,947 US20160279164A1 (en) | 2006-10-03 | 2016-05-20 | High-Molecular Weight Conjugate Of Resorcinol Derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006271425 | 2006-10-03 | ||
JP2006-271425 | 2006-10-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/311,086 A-371-Of-International US20090239782A1 (en) | 2006-10-03 | 2007-09-27 | High-molecular weight conjugate of resorcinol derivatives |
US14/497,703 Continuation US20150011715A1 (en) | 2006-10-03 | 2014-09-26 | High-Molecular Weight Conjugate Of Resorcinol Derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008041610A1 true WO2008041610A1 (fr) | 2008-04-10 |
Family
ID=39268471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/068841 WO2008041610A1 (fr) | 2006-10-03 | 2007-09-27 | Mélange d'un dérivé de résorcinol avec un polymère |
Country Status (7)
Country | Link |
---|---|
US (3) | US20090239782A1 (ja) |
EP (1) | EP2070971B1 (ja) |
JP (1) | JP5548364B2 (ja) |
CA (1) | CA2664852A1 (ja) |
ES (1) | ES2584840T3 (ja) |
TW (1) | TW200835510A (ja) |
WO (1) | WO2008041610A1 (ja) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008103353A1 (en) * | 2007-02-20 | 2008-08-28 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2009026658A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Ppar agonists |
WO2009041570A1 (ja) * | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
WO2009136572A1 (ja) * | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
US7662813B2 (en) | 2005-08-18 | 2010-02-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
JP2014501232A (ja) * | 2010-12-20 | 2014-01-20 | シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム | 抗腫瘍活性を有するアリールトリアゾール化合物 |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
JP2015124162A (ja) * | 2013-12-26 | 2015-07-06 | 日本化薬株式会社 | フェノール性水酸基を有するhsp90阻害剤のアクティブターゲティング型高分子誘導体及びその用途 |
WO2015125640A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
WO2015125641A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
WO2016136641A1 (ja) * | 2015-02-23 | 2016-09-01 | 日本化薬株式会社 | 生理活性物質結合ブロック共重合体 |
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
WO2017086235A1 (ja) * | 2015-11-18 | 2017-05-26 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
WO2017150256A1 (ja) | 2016-03-01 | 2017-09-08 | 日本化薬株式会社 | カンプトテシン類高分子誘導体を含有する医薬製剤 |
US9855339B2 (en) | 2014-12-26 | 2018-01-02 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical preparation of camptothecin-containing polymer derivative |
JP2018012694A (ja) * | 2016-07-12 | 2018-01-25 | 日本化薬株式会社 | ラパマイシン類結合ブロック共重合体 |
JPWO2017119272A1 (ja) * | 2016-01-08 | 2018-11-01 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
US10543281B2 (en) | 2015-09-03 | 2020-01-28 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition containing camptothecin polymer derivative |
CN111040180A (zh) * | 2020-01-15 | 2020-04-21 | 重庆大学 | 一种生物级联反应式光动力集成生物聚合物及其制备方法和应用 |
US10869937B2 (en) | 2016-07-30 | 2020-12-22 | Nippon Kayaku Kabushiki Kaisha | Polymer derivatives, and novel polymer derivative imaging probe using same |
US10973762B2 (en) | 2016-08-02 | 2021-04-13 | Nippon Kayaku Kabushiki Kaisha | Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101711732B1 (ko) * | 2014-04-30 | 2017-03-02 | 경북대학교 산학협력단 | 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도 |
WO2015167211A1 (ko) * | 2014-04-30 | 2015-11-05 | 경북대학교 산학협력단 | 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도 |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05955A (ja) * | 1990-11-07 | 1993-01-08 | Yasuhisa Sakurai | 水溶性高分子抗癌剤及び薬物担持用担体 |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
JPH10513187A (ja) * | 1995-01-30 | 1998-12-15 | エンゾン,インコーポレーテッド | 高分子量のポリマーを基剤とするプロドラッグ |
JP2894923B2 (ja) * | 1993-05-27 | 1999-05-24 | 日立造船株式会社 | ウォータージェット式双胴船のジェット水吸込口部構造 |
JP2000517304A (ja) * | 1996-08-20 | 2000-12-26 | エンゾン インコーポレーテッド | 高分子量のポリマーを基剤とするプロドラッグ |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
WO2003055860A1 (en) | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
JP2003527443A (ja) * | 2000-03-17 | 2003-09-16 | セル・セラピューティックス・インコーポレーテッド | ポリグルタミン酸−カンプトセシン結合体およびその調製方法 |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
WO2004050087A1 (en) | 2002-12-05 | 2004-06-17 | Vernalis (Cambridge) Limited | 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer |
WO2004056782A1 (en) | 2002-12-19 | 2004-07-08 | Vernalis (Cambridge) Limited | Pyrazole compounds |
WO2004072051A1 (en) | 2003-02-11 | 2004-08-26 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
WO2004096212A1 (en) | 2003-04-28 | 2004-11-11 | Vernalis (Cambridge) Limited | Pyrazole compounds as hsp90 inhibitors for the treatment of cancer |
WO2005000300A1 (en) | 2003-06-27 | 2005-01-06 | Vernalis (Cambridge) Limited | Substituted 5-membered ring compounds and their use |
WO2005018674A1 (ja) | 2003-08-22 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 |
WO2006055760A1 (en) | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2006095783A1 (ja) | 2005-03-09 | 2006-09-14 | Nippon Kayaku Kabushiki Kaisha | 新規なhsp90阻害剤 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467587A (en) * | 1974-07-11 | 1977-03-16 | Nestle Sa | Preparation of an asparagine or a glutamine |
US5234829A (en) * | 1984-08-07 | 1993-08-10 | Carnegie Mellon University | Purification method for materials having nick translation ability |
GB8500209D0 (en) * | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
US4734512A (en) * | 1985-12-05 | 1988-03-29 | Bristol-Myers Company | Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof |
CH667874A5 (fr) * | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments. |
US5182203A (en) * | 1989-03-29 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Bifunctional compounds useful in catalyzed reporter deposition |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
FR2698543B1 (fr) * | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5985548A (en) * | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
DE4307114A1 (de) * | 1993-03-06 | 1994-09-08 | Basf Ag | Verfahren zur Herstellung von Umsetzungsprodukten aus Polyasparaginsäureamid und Aminosäuren und ihre Verwendung |
US5571889A (en) * | 1994-05-30 | 1996-11-05 | Mitsui Toatsu Chemicals, Inc. | Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same |
US5552517A (en) * | 1995-03-03 | 1996-09-03 | Monsanto Company | Production of polysuccinimide in an organic medium |
DK0932399T3 (da) * | 1996-03-12 | 2006-05-15 | Pg Txl Co Lp | Vandoplöselige paclitaxel-prodrugs |
JP4420472B2 (ja) * | 1996-04-15 | 2010-02-24 | 旭化成株式会社 | 薬物複合体 |
US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
AU710156B2 (en) * | 1996-07-15 | 1999-09-16 | Kabushiki Kaisha Yakult Honsha | Taxane derivatives and drugs containing the same |
GB9625895D0 (en) * | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
ATE236657T1 (de) * | 1997-05-09 | 2003-04-15 | Deutsches Krebsforsch | Konjugat, umfassend einen folsäureantagonisten und einen träger |
EP1037649B1 (en) * | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
IN191203B (ja) * | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra | |
US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US20010041189A1 (en) * | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6376470B1 (en) * | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
JP3523821B2 (ja) * | 2000-02-09 | 2004-04-26 | ナノキャリア株式会社 | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
US20020161062A1 (en) * | 2001-11-06 | 2002-10-31 | Biermann Paul J. | Structure including a plurality of cells of cured resinous material, method of forming the structure and apparatus for forming the structure |
WO2002006279A1 (en) * | 2000-07-17 | 2002-01-24 | Oxigene Inc | Efficient method of synthesizing combretastatin a-4 prodrugs |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
ATE437647T1 (de) * | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
MXPA03007392A (es) * | 2001-02-20 | 2003-12-04 | Enzon Inc | Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos. |
US7138490B2 (en) * | 2001-06-20 | 2006-11-21 | Nippon Kayaku Kabushiki Kaisha | Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same |
CA2463902A1 (en) * | 2001-10-26 | 2003-05-01 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
ATE455561T1 (de) * | 2002-03-01 | 2010-02-15 | Univ Tulane | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden |
CN100475269C (zh) * | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
PL370866A1 (en) * | 2002-03-26 | 2005-05-30 | Banyu Pharmaceutical Co, Ltd. | Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
US6596757B1 (en) * | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
JP2003342168A (ja) * | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
US7169892B2 (en) * | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
JP4757633B2 (ja) * | 2003-03-20 | 2011-08-24 | 日本化薬株式会社 | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
AU2004224530A1 (en) * | 2003-03-26 | 2004-10-07 | Ltt Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targenting drug delivery and sustained drug release |
CA2542834C (en) * | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
FR2862536B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
NZ549010A (en) * | 2004-01-07 | 2010-07-30 | Seikagaku Kogyo Co Ltd | Hyaluronic acid derivative and drug containing the same |
BRPI0515573A (pt) * | 2004-09-22 | 2008-07-29 | Nippon Kayaku Kk | copolìmero por blocos, preparação de micela e agente anticáncer contendo a mesma como o ingrediente ativo |
CA2588124A1 (en) * | 2004-11-16 | 2006-06-08 | Hyperion Catalysis International, Inc. | Method for preparing supported catalysts from metal loaded carbon nanotubes |
EP1857489A4 (en) * | 2005-03-09 | 2010-06-23 | Toray Industries | MICROPARTICLE AND PHARMACEUTICAL COMPOSITION |
US8399464B2 (en) * | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
JP2008137894A (ja) * | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
US7700709B2 (en) * | 2005-05-11 | 2010-04-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of cytidine metabolic antagonist |
US20090275732A1 (en) * | 2005-05-12 | 2009-11-05 | Ichiro Hirotsu | Agent for improving circulatory disorder |
EP1948240A2 (en) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs and derivatives |
KR20080106254A (ko) * | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | 탁산류의 고분자 결합체 |
AU2007252678A1 (en) * | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of podophyllotoxin |
CN101489592A (zh) * | 2006-07-19 | 2009-07-22 | 日本化药株式会社 | 考布他汀的高分子量偶联物 |
JP5503872B2 (ja) * | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
EP2090607B1 (en) * | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
EP2206502B1 (en) * | 2007-09-28 | 2018-09-12 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of steroid |
EP2258397B1 (en) * | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of physiologically active substance |
WO2009136572A1 (ja) * | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
WO2010131675A1 (ja) * | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
-
2007
- 2007-09-27 ES ES07828587.1T patent/ES2584840T3/es active Active
- 2007-09-27 JP JP2008537500A patent/JP5548364B2/ja not_active Expired - Fee Related
- 2007-09-27 US US12/311,086 patent/US20090239782A1/en not_active Abandoned
- 2007-09-27 WO PCT/JP2007/068841 patent/WO2008041610A1/ja active Application Filing
- 2007-09-27 EP EP07828587.1A patent/EP2070971B1/en not_active Not-in-force
- 2007-09-27 CA CA002664852A patent/CA2664852A1/en not_active Abandoned
- 2007-10-02 TW TW096136886A patent/TW200835510A/zh unknown
-
2014
- 2014-09-26 US US14/497,703 patent/US20150011715A1/en not_active Abandoned
-
2016
- 2016-05-20 US US15/159,947 patent/US20160279164A1/en not_active Abandoned
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3310000B2 (ja) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
JPH05955A (ja) * | 1990-11-07 | 1993-01-08 | Yasuhisa Sakurai | 水溶性高分子抗癌剤及び薬物担持用担体 |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
JP2894923B2 (ja) * | 1993-05-27 | 1999-05-24 | 日立造船株式会社 | ウォータージェット式双胴船のジェット水吸込口部構造 |
JPH10513187A (ja) * | 1995-01-30 | 1998-12-15 | エンゾン,インコーポレーテッド | 高分子量のポリマーを基剤とするプロドラッグ |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
JP2000517304A (ja) * | 1996-08-20 | 2000-12-26 | エンゾン インコーポレーテッド | 高分子量のポリマーを基剤とするプロドラッグ |
JP2003527443A (ja) * | 2000-03-17 | 2003-09-16 | セル・セラピューティックス・インコーポレーテッド | ポリグルタミン酸−カンプトセシン結合体およびその調製方法 |
JP2005517675A (ja) * | 2001-12-21 | 2005-06-16 | ヴァーナリス(ケンブリッジ)リミテッド | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
WO2003055860A1 (en) | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
WO2004050087A1 (en) | 2002-12-05 | 2004-06-17 | Vernalis (Cambridge) Limited | 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer |
JP2006510627A (ja) * | 2002-12-05 | 2006-03-30 | ヴァーナリス(ケンブリッジ)リミテッド | 癌治療用のhsp90阻害剤としての3−(2−ヒドロキシ−フェニル)−1h−ピラゾール−4−カルボン酸アミド誘導体 |
WO2004056782A1 (en) | 2002-12-19 | 2004-07-08 | Vernalis (Cambridge) Limited | Pyrazole compounds |
JP2006511571A (ja) * | 2002-12-19 | 2006-04-06 | ヴァーナリス(ケンブリッジ)リミテッド | ピラゾール化合物 |
WO2004072051A1 (en) | 2003-02-11 | 2004-08-26 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
JP2006517572A (ja) * | 2003-02-11 | 2006-07-27 | ヴァーナリス(ケンブリッジ)リミテッド | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
WO2004096212A1 (en) | 2003-04-28 | 2004-11-11 | Vernalis (Cambridge) Limited | Pyrazole compounds as hsp90 inhibitors for the treatment of cancer |
JP2006524673A (ja) * | 2003-04-28 | 2006-11-02 | ヴァーナリス(ケンブリッジ)リミテッド | ガンの処置のためのhsp90阻害剤としてのピラゾール化合物 |
WO2005000300A1 (en) | 2003-06-27 | 2005-01-06 | Vernalis (Cambridge) Limited | Substituted 5-membered ring compounds and their use |
WO2005018674A1 (ja) | 2003-08-22 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 |
WO2006055760A1 (en) | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2006095783A1 (ja) | 2005-03-09 | 2006-09-14 | Nippon Kayaku Kabushiki Kaisha | 新規なhsp90阻害剤 |
Non-Patent Citations (5)
Title |
---|
"Hsp90 inhibitors as novel cancer chemotherapeutic agents", TRENDS MOL MED., vol. 8, no. 4, 2002, pages 55 - 61 |
"The clinical applications of heat shock protein inhibitors in cancer - present and future", CURR. CANCER DRUG TARGETS., vol. 3, no. 5, October 2003 (2003-10-01), pages 385 - 390 |
LEN NECKERS: "Hsn90 inhibitors as nobel cancer chemotherapeutic agents", TRENDS IN MOLECULAR MEDICINE, vol. 8, no. 4, SUPPL. 1, 2002, pages 55 - 61, XP002246588 * |
See also references of EP2070971A4 |
VILENCHIK, M. ET AL.: "Targeting wide-range oncogenic transformation via PU24FC1, A specific inhibitor of tumor Hsp90", CHEM. BIOL., vol. 11, 2004, pages 787 - 797, XP025940201, DOI: doi:10.1016/j.chembiol.2004.04.008 |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
US7662813B2 (en) | 2005-08-18 | 2010-02-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
WO2008103353A1 (en) * | 2007-02-20 | 2008-08-28 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2009026658A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Ppar agonists |
WO2009041570A1 (ja) * | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
JP5366940B2 (ja) * | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
JPWO2009136572A1 (ja) * | 2008-05-08 | 2011-09-08 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
WO2009136572A1 (ja) * | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
JP2014501232A (ja) * | 2010-12-20 | 2014-01-20 | シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム | 抗腫瘍活性を有するアリールトリアゾール化合物 |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
JP2015124162A (ja) * | 2013-12-26 | 2015-07-06 | 日本化薬株式会社 | フェノール性水酸基を有するhsp90阻害剤のアクティブターゲティング型高分子誘導体及びその用途 |
JPWO2015125640A1 (ja) * | 2014-02-19 | 2017-03-30 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
WO2015125641A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 |
WO2015125640A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
JPWO2015125641A1 (ja) * | 2014-02-19 | 2017-03-30 | 日本化薬株式会社 | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 |
US9993569B2 (en) | 2014-12-26 | 2018-06-12 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical preparation of camptothecin-containing polymer derivative |
US9855339B2 (en) | 2014-12-26 | 2018-01-02 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical preparation of camptothecin-containing polymer derivative |
WO2016136641A1 (ja) * | 2015-02-23 | 2016-09-01 | 日本化薬株式会社 | 生理活性物質結合ブロック共重合体 |
US10357573B2 (en) | 2015-02-23 | 2019-07-23 | Nippon Kayaku Kabushiki Kaisha | Block copolymer conjugate of physiologically active substance |
US10543281B2 (en) | 2015-09-03 | 2020-01-28 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition containing camptothecin polymer derivative |
WO2017086235A1 (ja) * | 2015-11-18 | 2017-05-26 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
JPWO2017086235A1 (ja) * | 2015-11-18 | 2018-08-30 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
US10945997B2 (en) | 2016-01-08 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of macrolide immunosuppressant |
JPWO2017119272A1 (ja) * | 2016-01-08 | 2018-11-01 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
WO2017150256A1 (ja) | 2016-03-01 | 2017-09-08 | 日本化薬株式会社 | カンプトテシン類高分子誘導体を含有する医薬製剤 |
JP2018012694A (ja) * | 2016-07-12 | 2018-01-25 | 日本化薬株式会社 | ラパマイシン類結合ブロック共重合体 |
US10869937B2 (en) | 2016-07-30 | 2020-12-22 | Nippon Kayaku Kabushiki Kaisha | Polymer derivatives, and novel polymer derivative imaging probe using same |
US10973762B2 (en) | 2016-08-02 | 2021-04-13 | Nippon Kayaku Kabushiki Kaisha | Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition |
CN111040180A (zh) * | 2020-01-15 | 2020-04-21 | 重庆大学 | 一种生物级联反应式光动力集成生物聚合物及其制备方法和应用 |
CN111040180B (zh) * | 2020-01-15 | 2021-12-07 | 重庆大学 | 一种生物级联反应式光动力集成生物聚合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2070971A4 (en) | 2013-06-05 |
CA2664852A1 (en) | 2008-04-10 |
JPWO2008041610A1 (ja) | 2010-02-04 |
US20160279164A1 (en) | 2016-09-29 |
ES2584840T3 (es) | 2016-09-29 |
US20150011715A1 (en) | 2015-01-08 |
EP2070971B1 (en) | 2016-06-22 |
TW200835510A (en) | 2008-09-01 |
JP5548364B2 (ja) | 2014-07-16 |
EP2070971A1 (en) | 2009-06-17 |
US20090239782A1 (en) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008041610A1 (fr) | Mélange d'un dérivé de résorcinol avec un polymère | |
JP5249016B2 (ja) | タキサン類の高分子結合体 | |
JP5503872B2 (ja) | 核酸系代謝拮抗剤の高分子誘導体 | |
JP5548365B2 (ja) | 核酸系代謝拮抗剤の高分子誘導体 | |
JP5181347B2 (ja) | ポドフィロトキシン類の高分子結合体 | |
JP5687899B2 (ja) | 生理活性物質の高分子結合体 | |
JP5366940B2 (ja) | 葉酸若しくは葉酸誘導体の高分子結合体 | |
JP5000512B2 (ja) | シチジン系代謝拮抗剤の高分子誘導体 | |
WO2010131675A1 (ja) | 水酸基を有する生理活性物質の高分子結合体 | |
JPWO2008010463A1 (ja) | コンブレタスタチン類の高分子結合体 | |
KR20140120316A (ko) | 표적화된 전달을 위한 소분자 인테그린 안타고니스트와 공유 결합된 키토산 | |
JP6830907B2 (ja) | マクロライド系免疫抑制剤の高分子誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07828587 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008537500 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12311086 Country of ref document: US Ref document number: 2007828587 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2664852 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |